MedTrace Logo

Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia

NCT00954486 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2016-03-24

No results posted yet for this study

Summary

The primary objective of this study is to assess the ability of epoetin alfa to raise hemoglobin (Hb) levels in elderly outpatients with unexplained anemia. The secondary objectives of this study are to assess the ability of epoetin alfa to improve physical function; cognitive function; and quality of life, and to assess the safety of epoetin alfa in the study population.

Conditions

Interventions

DRUG

Epoetin alfa

Epoetin alfa will be administered at 10,000 units/week

Sponsors & Collaborators

Principal Investigators

  • Stanley L Schrier, MD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00954486 on ClinicalTrials.gov